ATE524452T1 - Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. - Google Patents
Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen.Info
- Publication number
- ATE524452T1 ATE524452T1 AT04758456T AT04758456T ATE524452T1 AT E524452 T1 ATE524452 T1 AT E524452T1 AT 04758456 T AT04758456 T AT 04758456T AT 04758456 T AT04758456 T AT 04758456T AT E524452 T1 ATE524452 T1 AT E524452T1
- Authority
- AT
- Austria
- Prior art keywords
- heart failure
- congestive heart
- sulfonamides
- compositions
- treating congestive
- Prior art date
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000013602 Cardiac Myosins Human genes 0.000 abstract 1
- 108010051609 Cardiac Myosins Proteins 0.000 abstract 1
- 208000008253 Systolic Heart Failure Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 210000002235 sarcomere Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45870203P | 2003-03-27 | 2003-03-27 | |
| PCT/US2004/009408 WO2004086865A1 (en) | 2003-03-27 | 2004-03-26 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE524452T1 true ATE524452T1 (de) | 2011-09-15 |
Family
ID=33131818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04758456T ATE524452T1 (de) | 2003-03-27 | 2004-03-26 | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7595322B2 (de) |
| EP (1) | EP1605752B1 (de) |
| JP (2) | JP4969238B2 (de) |
| AT (1) | ATE524452T1 (de) |
| ES (1) | ES2378620T3 (de) |
| WO (1) | WO2004086865A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2448582T (pt) | 2009-06-29 | 2017-07-10 | Agios Pharmaceuticals Inc | Compostos e composições terapêuticas |
| KR101699822B1 (ko) | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| AR092269A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| SG10201805033XA (en) | 2013-07-25 | 2018-07-30 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| SG11201705128VA (en) * | 2014-12-22 | 2017-07-28 | Consiglio Nazionale Ricerche | Products for the delivery of therapeutic/diagnostic compounds to the heart |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108430971A (zh) | 2015-09-29 | 2018-08-21 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| BR112018071048A2 (pt) | 2016-04-15 | 2019-05-07 | Janssen Sciences Ireland Uc | combinações e métodos que compreendem um inibidor da montagem de capsídeos |
| EP3515889A1 (de) | 2016-09-20 | 2019-07-31 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Trpv4-antagonisten |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP7106528B2 (ja) | 2016-09-20 | 2022-07-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | Ｔｒｐｖ４拮抗薬 |
| PE20200924A1 (es) | 2017-09-13 | 2020-09-14 | Amgen Inc | Compuestos de bisamida sustituida que activan el sarcomero cardiaco |
| HUE067913T2 (hu) | 2018-01-19 | 2024-11-28 | Cytokinetics Inc | Dihidrobenzofurán és indén analógok mint szív szarkomer gátlók |
| BR112020018601A2 (pt) | 2018-03-14 | 2020-12-29 | Janssen Sciences Ireland Unlimited Company | Regime de dosagem de modulador de montagem de capsídeo |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| BR112021017962A2 (pt) | 2019-03-12 | 2021-11-23 | Amgen Inc | Forma cristalina anidra de base livre do composto a, forma cristalina mono-hidratada de base livre do composto a, forma cristalina do composto a e diclorometano, forma cristalina do composto a e nitrometano, forma cristalina do composto a e hexafluoro-2-propanol, cocristal, composição farmacêutica, e, método para tratar insuficiência cardíaca |
| TW202108576A (zh) | 2019-05-06 | 2021-03-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB882090A (en) * | 1958-03-04 | 1961-11-08 | Geigy Ag J R | New sulphamoyl benzamides and processes for the production thereof |
| US3055905A (en) * | 1958-03-04 | 1962-09-25 | Geigy Chem Corp | New sulphamyl benzamides |
| US3567746A (en) * | 1968-07-10 | 1971-03-02 | Pennwalt Corp | N-aryl benzamides |
| EP0107735B1 (de) * | 1981-10-20 | 1988-10-19 | Mitsui Toatsu Kagaku Kabushiki Kaisha | Neue pyridazinon-abkömmlinge |
| GB9822238D0 (en) * | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| DE19912638A1 (de) * | 1999-03-20 | 2000-09-21 | Bayer Ag | Naphthylcarbonsäureamid-substituierte Sulfonamide |
| DE19929076A1 (de) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| US20050113450A1 (en) * | 2002-08-23 | 2005-05-26 | Atli Thorarensen | Antibacterial agents |
-
2004
- 2004-03-26 JP JP2006509380A patent/JP4969238B2/ja not_active Expired - Lifetime
- 2004-03-26 ES ES04758456T patent/ES2378620T3/es not_active Expired - Lifetime
- 2004-03-26 AT AT04758456T patent/ATE524452T1/de not_active IP Right Cessation
- 2004-03-26 US US10/550,398 patent/US7595322B2/en active Active
- 2004-03-26 WO PCT/US2004/009408 patent/WO2004086865A1/en not_active Ceased
- 2004-03-26 EP EP04758456A patent/EP1605752B1/de not_active Expired - Lifetime
-
2009
- 2009-09-03 US US12/553,311 patent/US7888373B2/en not_active Expired - Lifetime
-
2011
- 2011-01-18 US US13/008,432 patent/US8101620B2/en not_active Expired - Lifetime
- 2011-12-19 US US13/330,356 patent/US8202859B2/en not_active Expired - Fee Related
- 2011-12-27 JP JP2011284586A patent/JP2012092135A/ja active Pending
-
2012
- 2012-05-18 US US13/474,824 patent/US8367661B2/en not_active Expired - Fee Related
-
2013
- 2013-02-05 US US13/759,903 patent/US8604025B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4969238B2 (ja) | 2012-07-04 |
| US20110112154A1 (en) | 2011-05-12 |
| US20130267537A1 (en) | 2013-10-10 |
| US8101620B2 (en) | 2012-01-24 |
| JP2012092135A (ja) | 2012-05-17 |
| JP2006523234A (ja) | 2006-10-12 |
| US20070078126A1 (en) | 2007-04-05 |
| WO2004086865A1 (en) | 2004-10-14 |
| US8202859B2 (en) | 2012-06-19 |
| EP1605752A4 (de) | 2008-05-07 |
| US20100069370A1 (en) | 2010-03-18 |
| US20120088779A1 (en) | 2012-04-12 |
| US7595322B2 (en) | 2009-09-29 |
| US20120232092A1 (en) | 2012-09-13 |
| ES2378620T3 (es) | 2012-04-16 |
| EP1605752B1 (de) | 2011-09-14 |
| US8367661B2 (en) | 2013-02-05 |
| US8604025B2 (en) | 2013-12-10 |
| US7888373B2 (en) | 2011-02-15 |
| EP1605752A1 (de) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE524452T1 (de) | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. | |
| EA200700058A1 (ru) | Соединения, композиции и способы их использования | |
| MXPA05007513A (es) | Compuestos, composiciones y metodos. | |
| ATE494893T1 (de) | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer | |
| WO2003059258A3 (en) | Compositions and methods for treating heart failure | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| NO20075992L (no) | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav | |
| DK1044197T3 (da) | Piperidinylsubstituerede pyridylalkan-, -alken- og -alkyncarboxamider som cytostatiske midler og immunosuppressive midler | |
| ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| NO20075815L (no) | Formuleringer og metoder for behandling av amyloidose | |
| NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
| EA201000550A1 (ru) | Производные тиазола | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| WO2003059265A3 (en) | Compositions and methods for treating heart failure | |
| ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| ATE541848T1 (de) | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv | |
| ATE411984T1 (de) | Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten | |
| NO20051967L (no) | 3,4-disubstituerte pyroler og deres anvendelse ved behandling av inflammatoriske sykdommer. | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| EA200401032A1 (ru) | Антиинфарктные молекулы | |
| EA200702583A1 (ru) | Использование фенилсемикарбазонов для обработки семян | |
| NO20064793L (no) | Anvendelse av N-(2-arylpropionyl) sulfonamider for behandling av ryggmargskade. | |
| CY1106472T1 (el) | Η χρηση των παραγωγων υδροξυπυριδονης στην επουλωση πληγων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |